Lupartumab amadotin

Drug Profile

Lupartumab amadotin

Alternative Names: Anti-C4.4a antibody-drug conjugates - Bayer; Anti-LY6-PLAUR domain containing 3 antibody-drug conjugates - Bayer; Anti-LYPD3 antibody-drug conjugates - Bayer; BAY 1129980; LYPD3 protein-directed antibody-drug conjugates - Bayer

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Class Antineoplastics; Auristatins; Immunoconjugates
  • Mechanism of Action LYPD3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 21 Oct 2015 Phase-I development for Solid tumours (Late-stage disease) is ongoing in USA (NCT02134197)
  • 01 May 2014 Phase-I clinical trials in Solid tumours (late-stage disease, in patients known to express LYPD3 protein) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top